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e 11, 2013.his study sought to investigate the effect of renal denervation (RDN) in patients with treatment-resistant hypertension
according to the established deﬁnition (Joint National Committee VII and European Society of Hypertension/European
Society of Cardiology guidelines), that is, ofﬁce blood pressure (BP)140/90mmHg (with at least three antihypertensive
drugs, including a diuretic, in adequate doses) and conﬁrmed by 24-h ambulatory BP monitoring (ABPM).Background RDN emerged as an innovative interventional antihypertensive therapy. However, so far, only patients with severe
hypertension (systolic BP 160 mm Hg or 150 mm Hg for patients with type 2 diabetes) have been investigated.Methods In this study, there were 54 patients with moderate treatment-resistant hypertension (ofﬁce BP 140/90 mm Hg
and <160/100 mm Hg and diagnosis conﬁrmed by 24-h ABPM of 130/80 mm Hg) who underwent catheter-
based RDN using the Symplicity catheter (Medtronic Inc., Mountain View, California).Results Patients were treated with 5.1  1.4 antihypertensive drugs on average. Ofﬁce BP was signiﬁcantly reduced by
13/7mmHg6months after RDN (systolic: 1516mmHg vs. 13821mmHg, p<0.001; diastolic: 8311mmHg
vs. 75  11 mm Hg, p < 0.001). In patients (n ¼ 36) who underwent ABPM 6 months after treatment, there was
a reduction in average 24-h ABPM by 14/7 mm Hg (systolic: 150  16 mm Hg vs. 136  16 mm Hg, p < 0.001;
diastolic: 83  10 mm Hg vs. 76  10 mm Hg, p < 0.001). In 51% of patients, ofﬁce BP was controlled below
140/90 mm Hg after RDN. In addition, heart rate decreased from 67  11 to 63  10 beats/min (p ¼ 0.006).Conclusions Our data indicate that RDNmay reduce ofﬁce and 24-h ambulatory BP substantially in patients with moderate treatment-
resistant hypertension. (Renal Denervation in Treatment Resistant Hypertension; NCT01687725) (J Am Coll Cardiol
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013; revised manuscript received June 5, 2013,hypertension (TRH) is deﬁned as blood pressure (BP)
above treatment goal despite use of at least three antihyper-
tensive drugs in adequate doses from different classes
including a diuretic (according to Joint National Committee
[JNC]-7 [2] and European Society of Hypertension/Euro-
pean Society of Cardiology [ESH/ESC] guidelines criteria
[3,4]). Increased sympathetic activity plays a crucial patho-See page 1887genetic role in the development, maintenance, and aggrava-
tion of arterial hypertension (5), especially in TRH. Renal
denervation (RDN) has emerged as an interventional
approach to treat severe TRH by altering sympathetic
afferent and efferent nerve activity (6). The Symplicity
Hypertension (HTN)-1 (including extended long-term
follow-up) and HTN-2 studies have shown that
catheter-based RDN is an apparently safe approach for
achieving a substantial and sustained BP reduction in patients
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1881with severe TRH (7–9). Furthermore, after RDN, BP during
cardiopulmonary exercise was also reduced without alteration
in cardiorespiratory response (10).Moreover, regression of left
ventricular mass and improvement in diastolic function were
observed after RDN (11).One of themain inclusion criteria of
these studies was an ofﬁce systolic blood pressure (SBP)
160 mm Hg (150 mm Hg for patients with type 2 dia-
betes), despite the patient being treated with 3 or more anti-
hypertensive drugs (including 1 diuretic). The BP inclusion
criterion (SBP160mmHg) of the Symplicity studies is well
speciﬁed, but it is obvious that most patients with TRH have
ofﬁce SBP readings between 140 and 160 mm Hg (12).
In the face of the evidence from antihypertensive trials,
there is little doubt that these patients have a substantially
elevated CV risk. It has been repeatedly shown that irre-
spective of the starting BP level, even modest BP reduction is
accompanied by signiﬁcant attenuation of CV morbidity and
mortality (3,4,13,14). Therefore, new antihypertensive strat-
egies to achieve BP control, and therefore reduce CV risk, in
less severe forms of TRH are needed and should be carefully
evaluated; so far, only 1 small retrospective analysis focused
on the inﬂuence of RDN in moderate hypertensive cases (15).
We, therefore, initiated a prospective multicenter open-
label pilot study aimed at assessing the efﬁcacy of RDN in
cases of true moderate TRH. The antihypertensive efﬁcacy
of RDN in patients demonstrated by ambulatory blood
pressure monitoring (ABPM) to have true TRH was
assessed by ofﬁce BP and ABPM (16) change. This study
was undertaken in order to extend the evidence base of
RDN beyond the ﬁndings of previous trials that were
limited to severe TRH.Methods
Study cohort and design. In this investigator-initiated,
prospective, multicenter pilot study, 54 adult patients with
TRH deﬁned by JNC-7 (2) and ESH/ESC (3,4) guidelines
were consecutively included if the patient’s ofﬁce BP
was 140/90 mm Hg and <160/100 mm Hg. In addition,
in every patient, true resistant hypertension was conﬁrmed by
initial 24-h ABPM (130/80 mm Hg), thereby excluding
“white coat” (elevated ofﬁce BP, but normal values out of the
ofﬁce, either on ABPM or home blood pressure monitoring
[HBPM]) or pseudoresistant hypertension; but in contrast to
Symplicity HTN-2 trial, no home BP measurement for
2 weeks was required (8). Patients were required to be on
an unchanged antihypertensive drug regimen for at least
2 months, without any allowance for dose or regimen
adjustments. Thus, ofﬁce BP measurements and 24-h
ABPM were taken under stable conditions. Main exclusion
criteria were renal artery anatomy (main renal arteries <4
mm in diameter or <20 mm in length, hemodynamically or
anatomically signiﬁcant renal artery abnormality or stenosis
in either renal artery, history of renal artery intervention
including balloon angioplasty or stenting, multiple main
renal arteries in either kidney) and any secondary cause ofhypertension, except for treated
obstructive sleep apnea syndrome
and chronic kidney disease.
Altogether, 19% of patients
referred to our tertiary universi-
ties’ outpatient clinics were
eligible for this pilot study and
were treated between February
2011 and March 2012. The study
protocol was approved by the
local ethics committees from the
2 participating centers, and the
study was performed according to
Declaration of Helsinki and
Good Clinical Practice guide-
lines. Written informed consent
was obtained from all patients
before study entry. The study was
registered at U.S. National
Institutes of Health Clinical Trials website (NCT01687725).
Ofﬁce and 24-h ambulatory BP. Ofﬁce BP was measured
in both arms after 5 min of rest in a sitting position, with
an oscillometric device (study center Erlangen: Dinamap
Pro100V2 [Criticon, Norderstedt, Germany]; study center
Homburg/Saar: Omron HEM-705 monitor [Omron
Healthcare, Vernon Hills, Illinois], with a printer for
documentation). Subsequent BP measurements were made
in the arm with the higher BP reading, and the average of
the last 3 measurements was taken. Ambulatory 24-h BP
measurements were taken with an automatic portable
device that was validated according the ESH International
Protocol (17) (e.g., Spacelab no. 90207, Redmont, Cal-
ifornia) prior to RDN. Twelve patients refused ABPM,
and in 6 patients, data readings were insufﬁcient (in 5 cases
there were no nighttime recordings; and in 1 case,
recordings <80% successful were obtained) 6 months after
RDN. Hence, in a subgroup (n ¼ 36), successful ABPM
was measured 6 months after RDN. In every patient, the
same device was used before and 6 months after RDN.
Patients were divided according their dipping pattern into
“dippers” (night-time BP fall >10%) and “non-dippers”
(night-time BP fall <10%).
Heart rate was obtained using 12-lead electrocardiog-
raphy, performed 10 min after supine rest at standard
sensitivity (10 mm ¼ 1 mV) and a paper speed of 50 mm/s.
Catheter-based renal denervation. For RDN, the femoral
artery was accessed with standard endovascular technique.
Radiofrequency catheter (Symplicity RDN system, Med-
tronic Inc.) was advanced in each renal artery by angiog-
raphy. As described previously in detail (7), at least 4
radiofrequency ablations (energy delivery for 120 s each),
controlled and regulated by a radiofrequency generator, were
applied within the lengths of each renal artery. Patients
received 5,000 IU of heparin to achieve an activated clotting
time of >250 s. Diffuse visceral pain during the procedure
was managed with anxiolytics and narcotics.
Table 1 Clinical Characteristics
Age, yrs 63.6  11
Male 38 (70%)
BMI, kg/m2 31.1  5.2
Antihypertensive (n) 5.1  1.4
RAS-modulating agents (at least one) 49 (91%)
Calcium channel blockers 45 (83%)
Beta-blockers 44 (81%)
Diuretics 51 (94%)
Central sympatholytics 22 (41%)
Aldosterone antagonists 7 (13%)
Vasodilators 14 (26%)
CHD 14 (26%)
Diabetes mellitus type 2 27 (50%)
eGFR (ml/min/1.73 m2)* 69.5  21
Values aremean SD or n (%). *According to Modiﬁcation of Diet in Renal Disease (MDRD) formula.
BMI ¼ body mass index; CHD ¼ coronary heart disease; eGFR ¼ estimated glomerular ﬁltration
rate.
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1882Statistical analyses. All analyses were performed using
SPSS version 19.0 software (SPSS Inc., Chicago, Illinois).
Normal distribution of data was conﬁrmed by Kolmogorov-
Smirnov test before further analyses. Data were compared by
paired and unpaired Student t-tests and by Wilcoxon and
McNemar tests where appropriate. Data are mean  SD.
Univariate correlation was performed using the Pearson
correlation coefﬁcient. A two-sided p value of <0.05 was
considered statistically signiﬁcant.Figure 1 Effect of Renal Denervation on Ofﬁce Blood Pressure
(A) Ofﬁce systolic blood pressure at baseline and at 3 and 6 months after RDN.
(B) Ofﬁce diastolic blood pressure (BP) at baseline and at 3 and 6 months after
RDN. Values are mean  SD. RDN ¼ renal denervation.Results
Clinical characteristics. Clinical characteristics of the
study population are shown in Table 1. Most patients were
middle-aged, male, and overweight. The mean ofﬁce BP was
151/83 mm Hg, and mean 24-h ambulatory BP was 130/
80 mm Hg (systolic: 149  13 mm Hg, and diastolic: 81 
11 mm Hg) in all patients, thereby conﬁrming true resistant
hypertension and excluding “white coat” hypertension (18).
Patients were treated with a mean of 5.1  1.4 antihyper-
tensive drugs, and 3 patients were not receiving diuretic
therapy because of acknowledged contraindications such as
secondary polycythemia or documented intolerance.
No severe adverse events were observed, including renal
vascular and renal damage, associated with the procedure.
Ofﬁce BP. Three months after RDN, ofﬁce BP was
reduced (systolic: 151  6 mm Hg vs. 146  23 mm Hg,
p ¼ 0.164; diastolic: 83  11 mm Hg vs. 79  12 mm Hg,
p ¼ 0.011) (Figs. 1A, 1B, and 2), and 6 months
after RDN, a further BP reduction was documented
(systolic: 151  6 mm Hg vs. 138  21 mm Hg, p < 0.001;
diastolic: 83  11 mm Hg vs. 75  11 mm Hg, p < 0.001)
(Figs. 1A, 1B, and 2). In 51% of patients, ofﬁce BP was
controlled after RDN, deﬁned as ofﬁce BP<140/90 mmHg.
Additionally, 61.1% of patients had an ofﬁce SBP reduc-
tion of 10 mm Hg 6 months after RDN (deﬁned as
treatment response).24-h ABPM. In patients with available ABPM before
and after RDN (n ¼ 36), ofﬁce BP was reduced (systolic:
151  5 mm Hg vs. 142  20 mm Hg, p ¼ 0.012; diastolic:
84  10 mm Hg vs. 79  11 mm Hg, p ¼ 0.003) 3 months
after RDN. There was a further reduction of SBP
(151  5 mm Hg vs. 133  19 mm Hg, p < 0.001) and
diastolic BP (84  10 mm Hg vs. 75  11 mm Hg,
p < 0.001) 6 months after RDN (Fig. 3). In addition,
we observed a reduction in mean 24-h ABPM (systolic:
150  16 mm Hg vs. 136  16 mm Hg, p < 0.001; dia-
stolic: 83  10 mm Hg vs. 76  10 mm Hg, p < 0.001)
6 months after RDN (Fig. 3). RDN reduced both daytime
ABP, by 14/6 mm Hg (systolic: 154  17 mm Hg vs.
140  16 mm Hg, p < 0.001; diastolic: 85  11 mm Hg vs.
79  11 mm Hg, p ¼ 0.001) and nighttime ABP,
Figure 2 Blood Pressure Changes in All Patients
Absolute change in ofﬁce systolic (open bars) and diastolic (solid bars) blood
pressure in all patients (n ¼ 54) after renal denervation. Mean  SD. p values are
comparisons with baseline values. DBP ¼ diastolic blood pressure; SBP ¼ systolic
blood pressure.
Figure 4 Effect of Renal Denervation on Ofﬁce Heart Rate
Ofﬁce heart rate at baseline and follow-up. Values are means  SD.
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1883by 13/5 mm Hg (systolic: 141  17 mm Hg vs. 128 
18 mm Hg, p < 0.001; diastolic: 75  11 mm Hg vs.
70  11 mm Hg, p ¼ 0.005). Dipping pattern was absent in
60% before RDN and in 51.4% after RDN (p ¼ 0.607),
respectively.
Heart rate. Six months after RDN, HR was also sig-
niﬁcantly reduced (67  11 mm Hg vs. 63  10 beats/min,Figure 3
Blood Pressure Changes in Patients With
Available Ambulatory Blood Pressure Monitoring
Before and After Renal Denervation
Absolute change in ofﬁce systolic (open bars) and diastolic (solid bars) blood
pressure and 24-h ambulatory systolic (open bars) and diastolic (solid bars) blood
pressure in patients with available ambulatory blood pressure monitoring (ABPM)
before and after renal denervation (n ¼ 36). Values are means  SD. p values are
comparisons with baseline values. Abbreviations as in Figure 2.p¼ 0.006) (Fig. 4). The change of HR did not correlate with
the reduction of SBP at 3 months (r ¼ 0.042, p ¼ 0.768)
and at 6 months (r ¼ 0.095, p ¼ 0.538), indicating that
RDN resulted in a reduction of HR independently of its BP-
lowering effects. In accordance, HR reduction did not differ
between nonresponder and responder of SBP, deﬁned as
a decrease of SBP 10 mm Hg at 6 months after RDN.
Furthermore, SBP reduction did not differ between nonre-
sponder and responder of HR, deﬁned as HR decrease
of 2 beats/min (i.e., median HR change) at 6 months
after RDN (Fig. 5).
Medication. In 37% of patients, antihypertensive medica-
tion was reduced during the 6-month follow-up period
despite the guidance of the study protocol not to do so.
According to an exploratory analysis, BP dropped by
13/6 mm Hg (p ¼ 0.024/0.015) in those whose medication
was maintained and by 13/9 mm Hg (p ¼ 0.024/0.007) in
those whose medication was reduced 6 months after RDN.
Antihypertensive medication was not increased in any
patient.
Discussion
Recent studies have shown that RDN is an effective
antihypertensive approach for severe TRH, but its effect in
less severe forms of hypertension is unknown. In a retro-
spective, observational pilot study of an electronic medical
database, consisting of approximately 30,000 patients, the
prevalence of TRH in an ambulatory care setting was
assessed. It was reported that 9.1% of patients had TRH and
that their baseline SBP was 148 ( 20.8) mm Hg (12).
Ensuring a normal distribution, it is estimated that approxi-
mately 70% of patients had a SBP<160 mmHg. In contrast
Figure 5
Blood Pressure and Heart Rate Changes According
to Response Criteria
Absolute change in blood pressure (solid bars) and heart rate (open bars) at 6
months according to response criteria. Ofﬁce systolic blood pressure reduction
of 10 mm Hg at 6 months after renal denervation (RDN) is deﬁned as response;
ofﬁce heart rate reduction of 2 beats per minute at 6 months after RDN is
deﬁned as response. HR ¼ heart rate; other abbreviations as in Figure 2.
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moderateTRH,whose ofﬁceBPwas between140/90mmHg
and <160/100 mm Hg, despite use of 3 antihypertensive
drugs in full doses of different classes including a diuretic.
Of note, in every patient, true resistant hypertension was
conﬁrmed by 24-h ABPM, thereby excluding “white coat”
or pseudoresistant hypertension. According to the Spanish
registry study, 37.5% of patients with presumed TRH based
on ofﬁce BP values were found to have pseudoresistant
hypertension (i.e., 24-h ABPM <130/80 mm Hg) with
a substantial white coat effect (18). The major ﬁnding of our
prospective, multicenter study is that RDN resulted in
a signiﬁcant reduction of ofﬁce systolic and diastolic BP as
well as 24-h ABP in moderate true TRH.
Not surprisingly, the magnitude of ofﬁce BP reduction
after RDN and the responder rate (SBP reduction of at least
10 mm Hg after 6 months) was less pronounced than in
previous reports (7,8) because the entry BP criteria were lower
and pre-treatment BP was the major determinant of the
magnitude of BP fall (9,19). However, it has been repeatedly
shown that irrespective of starting BP level, even modest BP
reductions are accompanied by signiﬁcant attenuation of CV
morbidity and mortality (3,4,13,14). Although the prognosis
of TRH has not been robustly evaluated, recent evidence
indicates that TRH has a severe prognosis (20,21). Recently,
a single-center prospective study consisting of approximately
2,300 patients with uncomplicated hypertension with a mean
follow-up of 3.5 years showed that TRH leads to a higher
incidence of coronary artery damage (p ¼ 0.004), stroke(p¼ 0.027), and atrial ﬁbrillation (p¼ 0.001) than non-TRH
(22). Moreover, TRH was an independent predictor of
composite CV endpoints. Post-hoc analysis of randomized
trials analyzing the CV outcome in relation to achieved BP
levels during treatment have shown that, regardless of the
type of treatment, patients in whom SBP was reduced
to <140 mm Hg have a reduced incidence of CV events
compared with patients with SBP values >140 mm Hg
(23–26). Recently, a meta-analysis of major trials with
antihypertensive agents revealed that in patients with high
CV risk, the “residual risk,” meaning the risk level attained
by intensive therapy, can rarely be decreased below the cut-
off value deﬁning a high-risk condition (i.e., 20% risk of
CV events in 10 years). This indicates that delaying
therapeutic correction of CV risk factors until a high level is
achieved blunts the full beneﬁts of interventions (27).
Herein, in our study, over 50% of the patients were newly
controlled according to target ofﬁce BP values 6 months
after RDN.
RDN is associated with reductions of additional markers
of risk for CV morbidity and mortality. Amongst these are
reductions in markers of arterial stiffness (28), insulin
resistance (29,30) and left ventricular hypertrophy (11).
These ﬁndings suggest earlier consideration of therapeutic
RDN may result in further patient beneﬁts.
National and international guidelines provide thresholds
for ofﬁce BP values; however, threshold values of ABPM for
various severity stages of hypertension are not established. A
meta-analysis by Mancia and Parati (16) indicated that while
patients achieved target ofﬁce BP values (<140/90 mm Hg),
BP values measured by 24-h ABPM remained above the
corresponding value, 125 to 130/80 mm Hg, generally used
as a threshold for hypertension. Moreover, no prospective
study has been conducted in which patients were stratiﬁed
and treated based on ambulatory BP criteria, and subsequent
assessment of incidence of CV events during follow-up has
been performed. The value and magnitude of 24-h ABPM
reduction is comparable to that of ofﬁce BP reduction in our
study. This is in contrast to the ﬁndings in the Symplicity
studies but is related to the lower BP values before RDN. In
an Australian study consisting of 8,575 patients with a wide
range of BP values, it was found that the lower the BP before
the intervention, the closer the agreement between ABPM
and ofﬁce BP reductions were (31). No clear improvement
in dipping status was found 6 months after RDN, which is
not surprising as it has been shown that classiﬁcation of
patients into dippers and non-dippers is poorly reproducible
over time (32,33).
In approximately 40% of the patients, antihypertensive
therapy was reduced in the follow-up, which, however, is not
interchangeable with BP control. This unintended reduction
of antihypertensive medication implies that the reported
effect of BP reduction and control underestimates the real
BP reduction following RDN in our cohort of patients with
moderate TRH. It was the decision of the individual primary
care physician to reduce the antihypertensive medication
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unless SBP decreased <120 mm Hg or hypotensive side
effects became clinically relevant; no severe hypotensive
episode or clinical symptoms were observed. It seems this is
rather the result that physicians are willing to accept higher
levels of BP in TRH, a ﬁnding that has been reported in the
Supporting Hypertension Awareness and Research Europe-
wide (SHARE) survey (34) and other studies (35).
Our data are encouraging because they potentially indicate
an innovative interventional approach to treating patients
with moderate TRH, with the potential consequence of
lower CV morbidity and mortality. Furthermore, the
socioeconomic consequences need to be carefully analyzed
because both a lower incidence of CV complications and
reduced costs of antihypertensive medication need to be
balanced with the costs of RDN intervention.
Study limitations. A major limitation of our study is the
lack of a control group, and we feel our sample size is rather
small. The study population we examined represents a large
population of uncontrolled treated hypertensive patients.
We thus need a large-scale prospective, randomized, multi-
center, controlled clinical trial in this group of TRH patients
to precisely deﬁne the therapeutic role of RDN in moderate
TRH patients. Indeed, on March 7, 2013, Medtronic
submitted an Investigational Device Exemption to the U.S.
Food and Drug Administration to assess in a randomized,
controlled clinical trial the safety and efﬁcacy for RDN in
patients with moderate TRH (Symplicity HTN-4).
Conclusions
Our ﬁrst prospective pilot study indicates that RDN reduces
ofﬁce BP and 24-h ABPM substantially and to a similar
extent in patients with moderate true TRH.
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